These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22138537)

  • 1. Measurement of gender-sensitive treatment for women in mixed-gender substance abuse treatment programs.
    Tang Z; Claus RE; Orwin RG; Kissin WB; Arieira C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):160-6. PubMed ID: 22138537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender differences in the impact of comprehensive services in substance abuse treatment.
    Marsh JC; Cao D; D'Aunno T
    J Subst Abuse Treat; 2004 Dec; 27(4):289-300. PubMed ID: 15610830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women's programs versus mixed-gender day treatment: results from a randomized study.
    Kaskutas LA; Zhang L; French MT; Witbrodt J
    Addiction; 2005 Jan; 100(1):60-9. PubMed ID: 15598193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender-sensitive substance abuse treatment and arrest outcomes for women.
    Kissin WB; Tang Z; Campbell KM; Claus RE; Orwin RG
    J Subst Abuse Treat; 2014 Mar; 46(3):332-9. PubMed ID: 24209383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unit cost of counseling and patients length of stay in a residential drug treatment setting.
    Alemi F; Haack M; Holifield L; Claudio Y; Haqqi K
    J Ment Health Policy Econ; 2002 Sep; 5(3):103-7. PubMed ID: 12728196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of family-based substance abuse treatment.
    Morgan TB; Crane DR
    J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Service-level costing of drug abuse treatment.
    Anderson DW; Bowland BJ; Cartwright WS; Bassin G
    J Subst Abuse Treat; 1998; 15(3):201-11. PubMed ID: 9633032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in treatment retention among individuals with co-occurring substance abuse and mental health disorders.
    Choi S; Adams SM; Morse SA; MacMaster S
    Subst Use Misuse; 2015 Apr; 50(5):653-63. PubMed ID: 25587672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Client-Provider relationship in comprehensive substance abuse treatment: differences in residential and nonresidential settings.
    Shin HC; Marsh JC; Cao D; Andrews CM
    J Subst Abuse Treat; 2011 Dec; 41(4):335-46. PubMed ID: 21871770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding clinical complexity in delinquent youth: comorbidities, service utilization, cost, and outcomes.
    Hussey DL; Drinkard AM; Falletta L; Flannery DJ
    J Psychoactive Drugs; 2008 Mar; 40(1):85-95. PubMed ID: 18472668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis.
    Mojtabai R; Zivin JG
    Health Serv Res; 2003 Feb; 38(1 Pt 1):233-59. PubMed ID: 12650390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes among drug-dependent mothers treated in women-only versus mixed-gender programs.
    Hser YI; Evans E; Huang D; Messina N
    J Subst Abuse Treat; 2011 Sep; 41(2):115-23. PubMed ID: 21466942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hispanic parenting women in women-only versus mixed-gender drug treatment: a 10-year prospective study.
    Hser YI; Hunt SA; Evans E; Chang YJ; Messina NP
    Addict Behav; 2012 Jun; 37(6):729-35. PubMed ID: 22398357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis of three treatment modalities in a residential substance abuse program for women and children.
    McComish JF; Greenberg R; Ager J; Chruscial H; Laken MA
    Outcomes Manag Nurs Pract; 2000; 4(2):71-7. PubMed ID: 11111587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and program costs, and outcomes, of including gender-sensitive services in intensive inpatient programs for substance use.
    Hornack SE; Yates BT
    Eval Program Plann; 2017 Dec; 65():139-147. PubMed ID: 28869868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-service prevention programs for pregnant and parenting women with substance use and multiple vulnerabilities: Program structure and clients' perspectives on wraparound programming.
    Rutman D; Hubberstey C; Poole N; Schmidt RA; Van Bibber M
    BMC Pregnancy Childbirth; 2020 Aug; 20(1):441. PubMed ID: 32746789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.